The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 19, 2022
Filed:
Jan. 31, 2020
Applicant:
Cardioxyl Pharmaceuticals, Inc., Chapel Hill, NC (US);
Inventors:
Vincent Jacob Kalish, Annapolis, MD (US);
John Reardon, Chapel Hill, NC (US);
Frederick Arthur Brookfield, Oxfordshire, GB;
Stephen Martin Courtney, Oxfordshire, GB;
Lisa Marie Frost, Oxfordshire, GB;
John P. Toscano, Glen Arm, MD (US);
Assignee:
Cardioxyl Pharmaceuticals, Inc., Chapel Hill, NC (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/341 (2006.01); A61K 31/18 (2006.01); A61P 9/04 (2006.01); C07C 317/14 (2006.01); C07D 307/64 (2006.01); A61K 31/255 (2006.01); A61K 31/343 (2006.01); A61K 31/381 (2006.01); A61K 31/404 (2006.01); A61K 31/42 (2006.01); A61K 31/433 (2006.01); A61K 31/4436 (2006.01); A61K 31/5377 (2006.01); A61K 31/538 (2006.01); A61K 47/12 (2006.01); A61K 47/40 (2006.01); A61K 31/222 (2006.01); A61K 31/24 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/341 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 31/18 (2013.01); A61K 31/222 (2013.01); A61K 31/24 (2013.01); A61K 31/255 (2013.01); A61K 31/343 (2013.01); A61K 31/381 (2013.01); A61K 31/404 (2013.01); A61K 31/42 (2013.01); A61K 31/433 (2013.01); A61K 31/4436 (2013.01); A61K 31/538 (2013.01); A61K 31/5377 (2013.01); A61K 47/12 (2013.01); A61K 47/40 (2013.01); A61P 9/04 (2018.01); C07C 317/14 (2013.01); C07D 307/64 (2013.01);
Abstract
The present disclosure provides nitroxyl donating pharmaceutical compositions comprising N-substituted hydroxylamine derivatives. The compositions are highly efficacious in treating cardiovascular diseases (e.g., heart failure), have a suitable toxicological profile, and are sufficiently stable for intravenous or oral administration.